.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Novartis
AstraZeneca
Daiichi Sankyo
McKinsey
Harvard Business School
Accenture
Federal Trade Commission
Chinese Patent Office
Merck

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 065141

« Back to Dashboard
NDA 065141 describes CEFAZOLIN SODIUM, which is a drug marketed by Acs Dobfar, Facta Farma, West-ward Pharms Int, Steri Pharma, Teva Pharms, Hospira Inc, Sandoz, Glaxosmithkline, Samson Medcl, Hikma Farmaceutica, Qilu Pharm Co Ltd, Fresenius Kabi Usa, Cephazone Pharma, Abraxis Pharm, Watson Labs Inc, Bedford, and Aurobindo Pharma, and is included in thirty-one NDAs. It is available from seventeen suppliers. Additional details are available on the CEFAZOLIN SODIUM profile page.

The generic ingredient in CEFAZOLIN SODIUM is cefazolin sodium. There are twenty-seven drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.

Summary for NDA: 065141

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 065141

Ingredient-typeCephalosporins

Suppliers and Packaging for NDA: 065141

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CEFAZOLIN SODIUM
cefazolin sodium
INJECTABLE;INJECTION 065141 ANDA Samson Medical Technologies, L.L.C. 66288-1100 66288-1100-1 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 BAG (66288-1100-1)
CEFAZOLIN SODIUM
cefazolin sodium
INJECTABLE;INJECTION 065141 ANDA Samson Medical Technologies, L.L.C. 66288-1300 66288-1300-1 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 BAG (66288-1300-1)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 100GM BASE/VIAL
Approval Date:Nov 29, 2006TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 300GM BASE/VIAL
Approval Date:Nov 29, 2006TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
US Department of Justice
Cantor Fitzgerald
Harvard Business School
Mallinckrodt
McKesson
Queensland Health
Argus Health
Cipla
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot